G. Gillespie

发表

Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins

J. Markert, B. Roizman, G. Gillespie, 1998, Gene Therapy.

The use of a genetically engineered herpes simplex virus (R7020) with ionizing radiation for experimental hepatoma

B. Roizman, Y. Kataoka, R. Whitley, 2002, Gene Therapy.

Evaluation of immunologic parameters in canine glioma patients treated with an oncolytic herpes virus

E. Yang, D. Crossman, J. Koehler, 2021, Journal of translational genetics and genomics.

Genetically engineered HSV in the treatment of glioma: a review

R. Weichselbaum, J. Markert, B. Roizman, 2000, Reviews in medical virology.

Preclinical Evaluation of a Genetically Engineered Herpes Simplex Virus Expressing Interleukin-12

J. Markert, T. Schoeb, C. Palmer, 2012, Journal of Virology.

Differential retention of rhodamine 123 by avian sarcoma virus‐induced glioma and normal brain tissue of the rat in vivo

D. Bigner, S. K. Powers, W. Beckman, 1987, Cancer.

Macrophage‐Derived Growth Factor for Fibroblasts and Interleukin‐1 Are Distinct Entities

J. Estes, W. Pledger, G. Gillespie, 1984, Journal of leukocyte biology.

Inflammatory cells in solid murine neoplasms. II. Cell types found throughout the course of moloney sarcoma regression or progression

S. Russell, G. Gillespie, C. Cochrane, 1976, International journal of cancer.

B‐tropic oncornavirus production by BALB/c methylcholanthrene‐induced sarcoma cells

F. Jensen, S. Russell, G. Gillespie, 1978, International journal of cancer.

Studies on the role of macrophages in regulation of growth and metastasis of murine chemically induced fibrosarcomas

G. Gillespie, G. Wood, G. Gillespie, 1975, International journal of cancer.

Engineered herpes simplex virus expressing bacterial cytosine deaminase for experimental therapy of brain tumors

J. Markert, M. B. Guffey, S. Meleth, 2007, Cancer Gene Therapy.

Transcriptional Targeting of Adenovirally Delivered Tumor Necrosis Factor α by Temozolomide in Experimental Glioblastoma

R. Weichselbaum, D. Kufe, Xiaohong Yu, 2004, Cancer Research.

Safety and efficacy of intraventricular immunovirotherapy with oncolytic HSV-1 for CNS cancers.

J. Markert, R. Wechsler-Reya, S. Bae, 2022, Clinical Cancer Research.

Xanthine oxidase-dependent regulation of hypoxia-inducible factor in cancer cells.

Corinne E Griguer, G. Giles, J. R. Lancaster, 2006, Cancer research.

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

R. Martuza, S. Rabkin, T. Todo, 2000, Gene Therapy.

In vivo gene therapy of cancer with E. coli purine nucleoside phosphorylase.

J. Montgomery, G. Gillespie, W. Waud, 1997, Human gene therapy.

Oncolytic viral therapy: targeting cancer stem cells

G. Gillespie, G. Friedman, Justin C. Roth, 2014, Oncolytic virotherapy.

Acquisition of Temozolomide Chemoresistance in Gliomas Leads to Remodeling of Mitochondrial Electron Transport Chain*

J. Sarkaria, Corinne E Griguer, J. Markert, 2010, The Journal of Biological Chemistry.

CRAdRGDflt-IL24 virotherapy in combination with chemotherapy of experimental glioma

J. Markert, W. Grizzle, W. Grizzle, 2009, Cancer Gene Therapy.

Glioma stem cells and their roles within the hypoxic tumor microenvironment

A. Hjelmeland, Nathaniel H. Boyd, J. Bernstock, 2021, Theranostics.

Addition of carbonic anhydrase 9 inhibitor SLC-0111 to temozolomide treatment delays glioblastoma growth in vivo.

Emily R. Gordon, S. Cooper, S. Dedhar, 2017, JCI insight.

Human Malignant Glioma Therapy Using Anti-αVβ3 Integrin Agents

G. Gillespie, S. Chatterjee, A. Matsumura, 2004, Journal of Neuro-Oncology.

Combinatorial Drug Testing in 3D Microtumors Derived from GBM Patient-Derived Xenografts Reveals Cytotoxic Synergy in Pharmacokinomics-informed Pathway Interactions

Christopher D Willey, Joshua C Anderson, C. Willey, 2018, Scientific Reports.

Surface Expression of ASIC2 Inhibits the Amiloride-sensitive Current and Migration of Glioma Cells*

D. Benos, J. Markert, G. Kovacs, 2006, Journal of Biological Chemistry.

Acid-sensing Ion Channels in Malignant Gliomas*

D. Benos, J. Markert, K. Kirk, 2003, The Journal of Biological Chemistry.

Lyn kinase activity is the predominant cellular SRC kinase activity in glioblastoma tumor cells.

D. Flynn, G. Gillespie, Wenquan Wang, 2005, Cancer research.

A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses.

R. Weichselbaum, A. Cantor, J. Markert, 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

The One Health Consortium: Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Combination With a Checkpoint Inhibitor in Canine Patients With Sporadic High Grade Gliomas

M. R. Chambers, J. Markert, D. Crossman, 2020, Frontiers in Surgery.

Evaluation of the Safety and Biodistribution of M032, an Attenuated HSV-1 Virus Expressing hIL-12, After Intracerebral Administration to Aotus Non-Human Primates.

J. Markert, S. Carroll, J. Peggins, 2014, Human gene therapy. Clinical development.

CD133 Is a Marker of Bioenergetic Stress in Human Glioma

D. Benos, E. Gobin, P. Marcorelles, 2008, PloS one.

Enhanced Sensitivity of Patient-Derived Pediatric High-Grade Brain Tumor Xenografts to Oncolytic HSV-1 Virotherapy Correlates with Nectin-1 Expression

J. Markert, E. Beierle, J. Bernstock, 2018, Scientific Reports.

Modeling Physiologic Microenvironments in Three-Dimensional Microtumors Maintains Brain Tumor Initiating Cells.

A. Hjelmeland, Nathaniel H. Boyd, G. Gillespie, 2017, Journal of cancer stem cell research.

Evidence for mononuclear phagocytes in solid neoplasms and appraisal of their nonspecific cytotoxic capabilities.

S. Russell, G. Gillespie, J. Pace, 1980, Contemporary topics in immunobiology.

Oncolytic viral therapy: targeting cancer stem cells

G. Friedman, Justin C. Roth, G. Gillespie, 2014, Oncolytic virotherapy.

growth of the tumor. The signifi-Characterization and immunotherapeutic potential Ave. South, Birmingham, AL 35294, USA (lawrence.lamb@ccc.uab.edu). cant of T-cells controls and selected patients GBM explants may

J. Markert, S. Meleth, C. Suarez‐Cuervo, 2009 .

A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses.

R. Weichselbaum, A. Cantor, J. Markert, 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12

J. Markert, S. Meleth, G. Gillespie, 2005, Cancer Gene Therapy.

Antibiotic-mediated chemoprotection enhances adaptation of E. coli PNP for herpes simplex virus-based glioma therapy.

Jeong S. Hong, V. Gadi, J. Lindsey, 2005, Human gene therapy.